BridgeBio Pharma vs Ultragenyx Pharmaceutical
BBIO and RARE side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How BBIO and RARE compare
BridgeBio Pharma is the larger company, worth 9.6 times as much as Ultragenyx Pharmaceutical ($15.1B against $1.6B).
BridgeBio Pharma grew revenue faster over the last twelve months (167% versus 17.5% for Ultragenyx Pharmaceutical).
Ultragenyx Pharmaceutical scores higher on the StockData Score (9 against 3 for BridgeBio Pharma), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | BBIO | RARE |
|---|---|---|
| Size and price | ||
| Market cap | $15.1B | $1.6B |
| Share price | $77.36 | $15.90 |
| Change, 1 year | 18.9% | −51.7% |
| Change, 5 years | 95.6% | −79.2% |
| Beta (5Y) | 0.22 | 2.20 |
| Employees | 834 | 1,371 |
| StockData Score | ||
| Total score | 3 | 9 (better) |
| Valuation score | 0 | 1 (better) |
| Growth score | 2 | 2 |
| Performance score | 0 | 1 (better) |
| Health score | 1 | 5 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 15.9× | 2.2× (better) |
| FCF yield | −2.5% (better) | −31.2% |
| Growth | ||
| Revenue growth (TTM) | 167% (better) | 17.5% |
| Revenue growth, 5Y average | 127% (better) | 19.9% |
| Profitability | ||
| Gross margin | 94.3% | – |
| Operating margin | −38.5% (better) | −73.6% |
| Net margin | – | −81.7% |
| FCF margin | −39.1% (better) | −68.2% |
| Financial health | ||
| Interest coverage | −7.1× | – |
| Current ratio | 2.09 (better) | 1.73 |
| Altman Z-score | 0.13 (better) | −5.29 |
| Piotroski F-score | – | 5 |
| Dividends and buybacks | ||
| Buyback yield | 1.7% | – |
| Shareholder yield | 1.7% (better) | 0.00% |
| Ownership | ||
| Held by institutions | 99.4% | 108% |
| Held by insiders | 35.6% | 4.0% |
| Insider net buying, 12 months | −$84.8M | −$3.8M (better) |
| Superinvestors holding | 1 | – |
| Short interest, % of float | 16.6% | 25.0% |
Go deeper
- BBIO stock overview
- BBIO income statement
- BBIO valuation and score
- RARE stock overview
- RARE income statement
- RARE valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.